NCT07110103 2026-02-27
JACKPOT38
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Clinical Trials
24 trialsNCT07434518 2026-02-25
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting
NCT04913311 2026-02-19
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Recruiting
NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT07171606 2025-12-18
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Recruiting
NCT05522660 2025-12-11
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3 Recruiting
NCT06896422 2025-08-07
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 1 Recruiting
NCT06947694 2025-07-22
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
Xinqiao Hospital of Chongqing
Phase 2 Recruiting
NCT05486650 2025-07-14
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
Xinqiao Hospital of Chongqing
Recruiting
NCT05754203 2025-07-14
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Xinqiao Hospital of Chongqing
Phase NA Recruiting
NCT06977074 2025-05-23
PROPHET
Sun Yat-sen University
Phase 2 Recruiting
NCT04977791 2025-05-22
Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
Shanghai Chest Hospital
Recruiting
NCT06869239 2025-03-11
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Peking University Cancer Hospital & Institute
Recruiting
NCT06751849 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06751901 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06752044 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06752057 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06730503 2024-12-12
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Shanghai Chest Hospital
Recruiting
NCT06388031 2024-11-07
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04322578 2024-06-04
CONFIRM
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05615142 2024-04-17
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Sichuan University
Phase 1 Recruiting
NCT05735028 2024-04-17
The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
NCT05037825 2022-04-27
PARADIGM
VastBiome
Recruiting